A ground-breaking diabetes drug developed in Cuba will be tested in Europe next year and could be approved for use on the continent, according to a report in the Financial Times.
The paper states that Heberprot-P, an injectable biological medicine for diabetic foot ulcers, will be put through late-stage clinical trials involving 1,000 patients by Spanish pharmaceutical Praxis, following a deal between the company and the Cuban Center for Genetic Engineering and Biotechnology (CIGB).
Praxis chief executive, Javier Juliá, said the drugmaker had the rights to manufacture Heberprot-P, conduct clinical trials during 2013-14, and if approved, sell it across the EU as well as in Switzerland, Turkey, Brazil and Colombia.
According to the FT, such a move would represent a rare example of “western commercialisation of a drug produced in a Communist state”, although it could spark tensions with the USA which has a long-standing trade embargo with the Caribbean island.
Some leading international specialists remain unconvinced of the clinical benefits, safety and cost-effectiveness of Heberprot-P compared with other foot ulcer treatments for diabetics, and there is little data on the diabetes drug published in international peer-reviewed medical journals.
Dr Kristien Van Acker, of the International Working Group on the Diabetic Foot, convened by the International Diabetes Federatio, said: “Heberprot is set out as a wonderful product and people are working hard to commercialise it. But the studies don’t show proof it is better, and it is enormously costly.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…